ClinicalTrials.gg
CompletedNCT06710925Updated Mar 5, 2026

A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants

A Phase 3 interventional study of TNM001 and placebo in Respiratory Syncytial Virus Infections, sponsored by Zhuhai Trinomab Pharmaceutical Co., Ltd.. Completed at 2 sites in China. Open to participants aged 0 Weeks to 12 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Zhuhai Trinomab Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
0 Weeks to 12 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.

Enrollment
9th of 25
315 · median 132
Started
2024
with 6 others
Phase 3
6 of 30
2 open now
Registered
22nd of 30
by date
Lead sponsor
3 of 30
Zhuhai Trinomab Pharmaceutical Co., Ltd.

Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 9th largest by enrollment of the 25 interventional ones that give a count, is one of 7 that started in 2024, is one of 6 in phase 3, and was the 22nd registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 0 Weeks to 12 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Respiratory Syncytial Virus Infections with a site in China, or all of them as a file.
02

Study summary

This study is a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and immunogenicity of TNM001 in high-risk infants when entering their RSV season. Approximately 201 infants will be randomized in a ratio of 2:1 to receive TNM001 or placebo. All subjects will be followed for 270 days after dosing. This study will be conducted at approximately 20 sites in China.

03

Conditions studied

  • Respiratory Syncytial Virus Infections
04

Who can participate

Ages eligible
0 Weeks to 12 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.High risk infants under 1 year of age who are entering their first RSV season at the time of screening.
  • 2.Subject's legal representative(s) is(are) able to understand and comply with the requirements and procedures of the protocol,including scheduled visits and sample collection.
  • 3.Subject is available to complete the follow-up period.

Exclusion criteria

Exclusion Criteria:

  • 1. Any fever (> 38.0°C) or acute illness within 7 days prior to randomization
  • 2. History of RSV infection
  • 3. Being hospitalized at the time of randomization
  • 4. Currently receiving or expected to receive therapy during the study period.
  • 5. Renal impairment or hepatic dysfunction
  • 6. Nervous system disease or neuromuscular disease
  • 7. Known immunodeficiency including , mother with HIV infection unless the child's infection has been excluded.
  • 8. Known allergy history of immunoglobulin products, receipt or expected to receive immunoglobulins or blood products during the study period.
  • 9.Receipt of RSV vaccine or mAb
  • 10.Receiving blood products before randomization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
315 participants (actual)

Study arms

  • Experimental
    TNM001

    Biological: TNM001

  • Placebo comparator
    Placebo

    Biological: placebo

Interventions

  • BiologicalTNM001

    single dose intramuscular injection

  • Biologicalplacebo

    single dose intramuscular injection

06

What researchers measure

Primary outcomes

  1. Incidence of medically attended LRTI due to RT-PCR confirmed RSV

    Time frame: 150 days post dose

07

Study locations

2 sites
  • West China Second University Hospital, Sichuan University
    Chengdu, Sichuan 610000, China
  • Children's Hospital of Chongqing Medical University
    Chongqing, Sichuan 404100, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jul 2025, 7 months.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 7 months is below that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Nov 29, 2024
StartActual
Nov 28, 2024
Primary completionActual
Jul 27, 2025
CompletionActual
Dec 14, 2025
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06710925
Lead sponsor
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 29, 2024
Start date
Nov 28, 2024
Primary completion
Jul 27, 2025
Completion
Dec 14, 2025
Last update
Mar 5, 2026

Study contacts

Hanmin Liu
principal investigator · West China Second Hospital, Sichuan University
Enmei Liu
principal investigator · Children's Hospital of Chongqing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retavibart

Start the discussion